Treatment of non-small cell lung cancer comes to the age of immunotherapy / 解放军医学杂志
Medical Journal of Chinese People's Liberation Army
;
(12): 483-487, 2017.
Artículo
en Chino
| WPRIM
| ID: wpr-612540
ABSTRACT
Immune checkpoint inhibitors have become an important alternative for advanced non-small cell lung cancer (NSCLC) patients to surgery, chemotherapy, radiotherapy and targeted therapy. Monoclonal antibodies directed against immune checkpoint have shown better results in the application of first- or second-line treatment of NSCLC and for both squamous and non-squamous cell carcinoma patients, especially for those with positive PD-L1 tumor cells. Some comments will be made in present paper about the efficacy, biomarker, combined therapy and the resistant mechanism of immune checkpoint inhibitors.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Medical Journal of Chinese People's Liberation Army
Año:
2017
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS